Samsung Biologics stock

207940 · KRX · KRW

₩1,423,000.00Change from previous close: +0.85%Absolute change: +₩12,000.00

Close · November 16, 2026

Price history

−24.20% over the period

1 year: from ₩1,877,331.38 (November 17, 2025) to ₩1,423,000.00 (November 16, 2026), −24.20%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026₩1,423,000.00
October 30, 2026₩1,487,000.00
September 30, 2026₩1,381,619.88
August 31, 2026₩1,518,000.00
July 31, 2026₩1,485,000.00
June 30, 2026₩1,391,000.00
May 29, 2026₩1,363,000.00
April 30, 2026₩1,470,000.00
March 31, 2026₩1,504,000.00
February 27, 2026₩1,778,000.00
January 30, 2026₩1,745,000.00
December 30, 2025₩1,695,000.00
November 28, 2025₩1,607,000.00
November 17, 2025₩1,877,331.38

At a glance

  • The company

    Manufactures biopharmaceuticals and offers contract development and manufacturing services including antibody-drug conjugates and mRNA products

  • Latest results

    Quarter to September 30, 2026 · EPS ₩8,448.73 (estimate ₩9,841.69)

TickerLandia's take on Samsung Biologics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low₩1,150,000.00
52-wk high₩1,987,000.00

−28.38% from the 52-week high

Analysts · 27 analysts

Average target₩1,879,148.10+32.06% vs. price

Buy 25 · Hold 2 · Sell 0 · Buy

TickerLandia Fingerprint: Samsung Biologics

Compared with similar companies: very high earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Samsung Biologics is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Samsung Biologics's P/E today is 38.4, below the median of its last 8 fiscal years (92.4; between 45.8 and 224.4 from 2018 to 2025). Samsung Biologics's P/E (trailing 12 months): 33.4, −17% against the median of a group of 8 similar companies (40.2).

P/E compared with its history

Compared with 8 similar companies

Samsung Biologics's metrics compared with similar companies
MetricSamsung BiologicsPosition in the groupBand
P/E (trailing 12 months)33.4Low
Forward P/E30.4Middle
Operating margin45.5%High
ROE18.5%High
Debt/equity0.15Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Samsung Biologics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

₩1.32T

Latest quarter · Q2 2026

Net income

₩430.65B

Latest quarter · Q2 2026

Quarterly net margin

32.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
₩65.69T
P/E
33.4
EPS
₩45,556.40
Volume
54.88K
Daily trading
€69.99M

How Samsung Biologics is changing

All results
  • Revenue grew 31.4% a year on average over the last 5 years

  • Operating margin rose from 32.8% to 45.4%

  • Less cash than profit: free cash flow equal to 51% of net income

Returns

Samsung Biologics returns with dividends

₩1,000 invested in Samsung Biologics 5 years ago, on November 16, 2021, would be worth ₩1,073 today: +7.26% in total, +1.41% per year. This is the price return only: dividends are excluded.

PeriodSamsung Biologics₩1,000 becomes
1 month+9.63%₩1,096
6 months+0.28%₩1,003
Year to date−16.05%₩840
1 year−24.20%₩758
3 years+26.44%₩1,264
5 years+7.26%₩1,073
10 years+450.19%₩5,502

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Samsung Biologics: technical analysis

Samsung Biologics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 27.6% below its all-time closing high (₩1,965,000.00, January 15, 2026).

Trend
No clear trend
RSI (14 sessions)
50
Between 30 and 70
vs 200-session average
−4.67%

Support and resistance

Price areas where Samsung Biologics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance₩1,638,000.00+15.11%5 touches, last on August 20, 2026
  2. Resistance₩1,578,500.00+10.93%4 touches, last on November 6, 2026
  3. Resistance₩1,478,666.67+3.91%6 touches, last on October 26, 2026
  4. Last price₩1,423,000.00
  5. Support₩1,422,570.69−0.03%4 touches, last on October 1, 2026
  6. Support₩1,360,333.33−4.40%3 touches, last on October 30, 2026
  7. Support₩1,302,000.00−8.50%2 touches, last on July 9, 2026

Volatility and risk

Volatility (60 sessions, annualised)
48.5%
Largest fall in the last year
−39.85%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Samsung Biologics: seasonality

Average monthly price change over 10 years

+4.2%Jan−1.2%Feb−0.4%Mar+3.2%Apr+0.1%May+4.5%Jun+2.6%Jul+3.2%Aug+0.8%Sep+6.0%Oct−2.5%Nov+3.9%Dec

Over the last 10 years, the strongest month for Samsung Biologics has been October: +5.99% on average, positive in 7 years out of 10. The weakest has been November: −2.46% on average, positive in 4 years out of 9.

Show chart data
MonthAverageMedianPositive years
January+4.19%+4.93%7 of 10
February−1.20%−0.38%5 of 10
March−0.45%+2.97%6 of 10
April+3.17%+1.24%7 of 10
May+0.10%−0.76%5 of 10
June+4.53%−0.44%4 of 10
July+2.63%+4.39%6 of 10
August+3.21%+3.13%6 of 10
September+0.75%−1.88%3 of 10
October+5.99%+5.87%7 of 10
November−2.46%−1.25%4 of 9
December+3.88%+4.96%7 of 10

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Samsung Biologics and its competitors

The business centres on manufacturing biopharmaceutical products, which it also commercializes, distributes and sells. Its development work runs from cell line development and process development to analytical development and non-GMP and CGMP manufacturing. Downstream, it operates aseptic filling, freeze-drying, packaging and cold-chain logistics, alongside quality services such as stability studies, environmental monitoring and biosafety testing. Its portfolio also includes antibody-drug conjugates and mRNA products, and its customers and sales reach South Korea, Europe, the United States and other international markets.

Headquarters
Incheon, South Korea
Employees
5,326
Founded
2011
Chief executive
John Chongbo Rim
Samsung Biologics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Samsung Biologics207940$49.13B45.5%33.4+0.28%
CSLCSL$65.65B26.8%—+106.74%
Celltrion068270$36.68B31.6%26.4+19.29%
WuXi Biologics (Cayman)2269$24.52B32.4%35.1+38.78%
Innovent Biologics1801$18.84B7.4%111.5+2.32%
Sichuan Kelun-Biotech Biopharmaceutical6990$13.65B-0.2%—+0.78%

Same industry or related industries, similar size. Compare Samsung Biologics with its competitors · Full profile